Lead-212 (Eli Lilly And Company)

N/A

Report date: 2026/04/15 20:02:38

Base Information

Drug NameLead-212 (Eli Lilly And Company)
Drug Alias NameN/A
ClassificationRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Radionuclide Drug ConjugatesRadiation-emitting products > Nuclides > Lead > 212Pb
Mechanisms of ActionAnti-Trop-2
TargetsTumor-associated calcium signal transducer 2
Therapy Area/IndicationsPancreatic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesEli Lilly And Company
China Registration ClassN/A

Develop Information

Active CompaniesEli Lilly And Company
Inactive CompaniesN/A
Active IndicationsPancreatic Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A